Other Public Policy

One of the greatest challenges in biomedical and health research is ensuring that research findings are translated effectively and without undue delay from ‘bench to bedside’. As previous analysis has made clear, the time that elapses between discoveries in medical research and adoption in practice is important. Longer time lags mean a lower rate of return on the research investment, which makes it less attractive to do the research in the first place.

Just released is a collection of essays by Prof Tony Culyer, a founding father of health economics whose life’s work has been to bring clarity to health care decision making. The Humble Economist, published jointly by the University of York and the Office of Health Economics, is a distillation of Prof Culyer’s most important writings on health, health care and social decision making.

Over the past four years, OHE has been involved in research intended to examine more thoroughly the economic value of medical research in the UK. Understanding and maximising the value includes consideration of both direct and indirect returns when deciding research policies. Taking account of spillovers is essential.

Increasingly, governments in the UK and throughout Europe see R&D driven growth as the best way out of the financial crisis. The Government identifies the 'UK’s world-class research base' as a key driver of economic growth. But does the evidence of returns from public investment in R&D match the rhetoric?

Just released is the new OHE Guide to UK Health and Health Care Statistics, which provides both reliable up-to-date statistics and a basic guide to finding and using health statistics for the UK and, to some extent, other OECD countries.

OHE is making available as Occasional Papers drafts of two important chapters that will appear in the Oxford Handbook on the Economics of the Pharmaceutical Industry due out in 2012. One on access to drugs and vaccines in developing countries and the other on measuring value with pharmacoeconomics.

Forthcoming in the Oxford Handbook on the Economics of the Biopharmaceutical Industry, this paper describes the context of the problem of access to medicines in developing countries. The authors detail policies and proposals intended to increase access to both 'global' and 'neglected' diseases, including pricing, compulsory licensing, donations and 'push' and 'pull' mechanisms to stimulate R&D.

Released today is an OHE study commissioned by Cancer Research UK that explores the interdependence between publicly funded and charity funded medical research. In particular, the study focuses on whether and how changes in the levels of government funding affect private funding for charities and, more broadly, medical research and the UK economy as a whole.

Antimicrobial resistance (AMR) is becoming a major global public health threat. In this new OHE Research Paper, the authors identify barriers to the development of new products and recommend a hybrid push-pull approach to encouraging innovation.

The UK’s National Clinical Assessment Service (NCAS) provides advice to NHS managers about handling performance issues involving doctors, pharmacists and dentists. This post summarises an OHE research project meant to establish how much NHS managers value the NCAS’s services and the relative value placed on different attributes and types of service.